BBVA
VRNA

Banco Bilbao Vizcaya Argentaria’s Verona Pharma VRNA Stock Holding History

Banco Bilbao Vizcaya Argentaria’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-60,000
Closed -$303K – 759
2020
Q2 		$303K Buy
+60,000
New +$278K 0.01% 626

Other funds holding VRNA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Banco Bilbao Vizcaya Argentaria's VRNA Position: Q3 2020 in Review

Banco Bilbao Vizcaya Argentaria sold out of Verona Pharma (VRNA) in Q3 2020, closing a stake of 60,000 shares — an estimated $303K sold.

Banco Bilbao Vizcaya Argentaria first reported a position in VRNA in Q2 2020 and held it in 1 quarter. The position peaked at $303K in Q2 2020. 28 funds tracked by Wall St. Rank hold VRNA as of Q3 2020.

  • Banco Bilbao Vizcaya Argentaria reported no remaining Verona Pharma position as of Q3 2020 after selling out during the quarter.
  • Banco Bilbao Vizcaya Argentaria sold 60,000 Verona Pharma shares in Q3 2020, an estimated $303K.
  • Banco Bilbao Vizcaya Argentaria first reported a position in Verona Pharma in Q2 2020 and held it in 1 quarter.
  • Banco Bilbao Vizcaya Argentaria's Verona Pharma position peaked at $303K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2020.

Based on Banco Bilbao Vizcaya Argentaria's 13F filing for Q3 2020, filed 12 Nov 2020.